Kehua Bio has released a draft of its 2026 restricted stock incentive plan, proposing to grant a total of 20 million shares, representing approximately 3.89% of the company's total share capital. Of these, 17 million shares will be granted initially, accounting for about 3.30% of the total share capital, and 3 million shares will be reserved for future grants, representing about 0.58% of the total share capital. The grant price is 2.57 yuan per share. The incentive recipients include no more than six company directors and senior management personnel. In the first quarter of 2026, Kehua Bio achieved revenue of 395 million yuan and a net loss attributable to the parent company of 48.45 million yuan.
Shanghai Kehua Bio-Engineering Co LtdCompany announces restricted stock incentive plan, aligning management interests and potentially boosting morale.